Literature DB >> 31386258

Non-alcoholic fatty liver disease alters expression of genes governing hepatic nitrogen conversion.

Peter Lykke Eriksen1, Hendrik Vilstrup1, Kristoffer Rigbolt2, Malte P Suppli3, Michael Sørensen1, Sara Heebøll1, Sanne S Veidal2, Fillip K Knop3,4,5,6, Karen Louise Thomsen1.   

Abstract

BACKGROUND & AIMS: We recently showed that the functional capacity for ureagenesis is deficient in non-alcoholic fatty liver disease (NAFLD) patients. The aim of this study was to assess expression of urea cycle-related genes to elucidate a possible gene regulatory basis to the functional problem.
METHODS: Liver mRNA expression analyses within the gene pathway governing hepatic nitrogen conversion were performed in 20 non-diabetic, biopsy-proven NAFLD patients (8 simple steatosis; 12 non-alcoholic steatohepatitis [NASH]) and 12 obese and 14 lean healthy individuals. Sixteen NAFLD patients were included for gene expression validation. Relationship between gene expressions and functional capacity for ureagenesis was described.
RESULTS: Gene expression of most urea cycle-related enzymes were downregulated in NAFLD vs both control groups; markedly so for the urea cycle flux-generating carbamoyl phosphate synthetase (CPS1) (~3.5-fold, P < .0001). In NASH, CPS1 downregulation paralleled the deficit in ureagenesis (P = .03). Additionally, expression of several genes involved in amino acid uptake and degradation, and the glucagon receptor gene, were downregulated in NAFLD. Conversely, glutamine synthetase (GS) expression increased >1.5-fold (P ≤ .03), inversely related to CPS1 expression (P = .004).
CONCLUSIONS: NAFLD downregulated the expression of urea cycle-related genes. Downregulation of urea cycle flux-generating CPS1 correlated with the loss of functional capacity for ureagenesis in NASH. On gene level, these changes coincided with an increase in the major ammonia scavenging enzyme GS. The effects seemed related to a fatty liver as such rather than NASH or obesity. The findings support gene regulatory mechanisms involved in the deficient ureagenesis of NAFLD, but it remains unexplained how hepatocyte fat accumulation exerts these effects.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  amino acids; ammonia; glucagon; glutamine synthetase; non-alcoholic steatohepatitis; urea

Year:  2019        PMID: 31386258     DOI: 10.1111/liv.14205

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  14 in total

1.  Non-alcoholic Fatty Liver Disease: Also a Disease of the Brain? A Systematic Review of the Preclinical Evidence.

Authors:  Anne Catrine Daugaard Mikkelsen; Kristoffer Kjærgaard; Rajeshwar Prosad Mookerjee; Hendrik Vilstrup; Gregers Wegener; Cecilie Bay-Richter; Karen Louise Thomsen
Journal:  Neurochem Res       Date:  2022-03-01       Impact factor: 3.996

2.  Glucagon is associated with NAFLD inflammatory progression in type 2 diabetes, not with NAFLD fibrotic progression.

Authors:  Yuying Wang; Zhiqi Lin; Heng Wan; Wen Zhang; Fangzhen Xia; Yi Chen; Xiaoman Chen; Chiyu Wang; Chi Chen; Ningjian Wang; Yingli Lu
Journal:  Eur J Gastroenterol Hepatol       Date:  2021-12-01       Impact factor: 2.586

Review 3.  Quantifying the progression of non-alcoholic fatty liver disease in human biomimetic liver microphysiology systems with fluorescent protein biosensors.

Authors:  Manush Saydmohammed; Anupma Jha; Vineet Mahajan; Dillon Gavlock; Tong Ying Shun; Richard DeBiasio; Daniel Lefever; Xiang Li; Celeste Reese; Erin E Kershaw; Vijay Yechoor; Jaideep Behari; Alejandro Soto-Gutierrez; Larry Vernetti; Andrew Stern; Albert Gough; Mark T Miedel; D Lansing Taylor
Journal:  Exp Biol Med (Maywood)       Date:  2021-05-06

4.  Carbamoyl-Phosphate Synthase 1 as a Novel Target of Phomoxanthone A, a Bioactive Fungal Metabolite.

Authors:  Sara Ceccacci; Jana Deitersen; Matteo Mozzicafreddo; Elva Morretta; Peter Proksch; Sebastian Wesselborg; Björn Stork; Maria Chiara Monti
Journal:  Biomolecules       Date:  2020-06-02

5.  The liver-alpha cell axis associates with liver fat and insulin resistance: a validation study in women with non-steatotic liver fat levels.

Authors:  Christina Gar; Stefanie J Haschka; Stefanie Kern-Matschilles; Barbara Rauch; Vanessa Sacco; Cornelia Prehn; Jerzy Adamski; Jochen Seissler; Nicolai J Wewer Albrechtsen; Jens J Holst; Andreas Lechner
Journal:  Diabetologia       Date:  2020-12-04       Impact factor: 10.122

Review 6.  Cognitive Dysfunction in Non-Alcoholic Fatty Liver Disease-Current Knowledge, Mechanisms and Perspectives.

Authors:  Kristoffer Kjærgaard; Anne Catrine Daugaard Mikkelsen; Charlotte Wilhelmina Wernberg; Lea Ladegaard Grønkjær; Peter Lykke Eriksen; Malene Flensborg Damholdt; Rajeshwar Prosad Mookerjee; Hendrik Vilstrup; Mette Munk Lauridsen; Karen Louise Thomsen
Journal:  J Clin Med       Date:  2021-02-09       Impact factor: 4.241

7.  U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases.

Authors:  Huapeng Lin; Grace Lai-Hung Wong; Xinrong Zhang; Terry Cheuk-Fung Yip; Ken Liu; Yee Kit Tse; Vicki Wing-Ki Hui; Jimmy Che-To Lai; Henry Lik-Yuen Chan; Vincent Wai-Sun Wong
Journal:  Clin Mol Hepatol       Date:  2021-11-05

8.  Effects of Edible Insect Tenebrio molitor Larva Fermentation Extract as a Substitute Protein on Hepatosteatogenesis and Proteomic Changes in Obese Mice Induced by High-Fat Diet.

Authors:  Ju Ri Ham; Ra-Yeong Choi; Yongjin Lee; Mi-Kyung Lee
Journal:  Int J Mol Sci       Date:  2021-03-31       Impact factor: 5.923

9.  Hepatic microbiome in healthy lean and obese humans.

Authors:  Malte Palm Suppli; Jonatan Ising Bagger; Benjamin Lelouvier; Amandine Broha; Mia Demant; Merete Juhl Kønig; Charlotte Strandberg; Asger Lund; Tina Vilsbøll; Filip Krag Knop
Journal:  JHEP Rep       Date:  2021-04-27

10.  Functional Microbiomics Reveals Alterations of the Gut Microbiome and Host Co-Metabolism in Patients With Alcoholic Hepatitis.

Authors:  Bei Gao; Yi Duan; Sonja Lang; Dinesh Barupal; Tsung-Chin Wu; Luis Valdiviez; Bryan Roberts; Ying Yng Choy; Tong Shen; Gregory Byram; Ying Zhang; Sili Fan; Benjamin Wancewicz; Yan Shao; Kevin Vervier; Yanhan Wang; Rongrong Zhou; Lu Jiang; Shilpa Nath; Rohit Loomba; Juan G Abraldes; Ramon Bataller; Xin M Tu; Peter Stärkel; Trevor D Lawley; Oliver Fiehn; Bernd Schnabl
Journal:  Hepatol Commun       Date:  2020-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.